from our Health Desk
The CDC doesn’t wait for a pandemic to start; it uses a rigorous, preemptive process to develop Candidate Vaccine Viruses (CVVs). This protocol ensures that if a high-risk flu strain emerges, manufacturers can immediately pivot to mass production.
The Strategy: Stockpiling Readiness
While seasonal flu is deadly, a novel pandemic strain could be catastrophic. To mitigate this, the CDC partners with the WHO and BARDA to maintain a library of CVVs. These “seed” viruses are optimized to grow efficiently in chicken eggs, which remain the primary medium for global vaccine manufacturing.
The Production Process
- Surveillance & Selection: Using global data, scientists identify high-risk influenza sequences (specifically the HA and NA surface proteins).
- Genetic Engineering: These sequences are cloned into plasmids and introduced into Vero cells to “rescue” or jumpstart the virus.
- Egg Adaptation: Because Vero cells have low yields, the virus is transferred to embryonated chicken eggs for large-scale replication.
- Quality Control: Each CVV undergoes strict testing for genetic stability, purity, and “attenuation” (ensuring it is safe for vaccine use).
Impact and Future Outlook
The CDC has already developed over 100 CVVs, with dozens distributed to manufacturers for stockpiling. While egg-based production is the current standard, it has vulnerabilities like mutation risks and supply chain fragility. As a result, the CDC is increasingly exploring recombinant protein and mRNA platforms to allow for even faster responses in the future.